Compound class:
Synthetic organic
Comment: The structure for rocbrutinib was obtained from proposed INN list 129 (August 2023) where it is described as Bruton's tyrosine kinase inhibitor and antineoplastic agent. It is one of the compounds claimed in patent WO2019161152A1 (Newave Pharmaceutical) [1]. LP-168 is the one lead in Newave's development pipeline that fits the profile of a potential BTK inhibitor, but whose target is undisclosed.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Database Links ![]() |
|
CAS Registry No. | 2485861-07-0 (source: WHO INN record) |
GtoPdb PubChem SID | 485205996 |
PubChem CID | 139416847 |
Search Google for chemical match using the InChIKey | OYJVFTNYBWVQHA-SANMLTNESA-N |
Search Google for chemicals with the same backbone | OYJVFTNYBWVQHA |
UniChem Compound Search for chemical match using the InChIKey | OYJVFTNYBWVQHA-SANMLTNESA-N |
UniChem Connectivity Search for chemical match using the InChIKey | OYJVFTNYBWVQHA-SANMLTNESA-N |